AR110963A1 - Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende - Google Patents
Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprendeInfo
- Publication number
- AR110963A1 AR110963A1 ARP180100277A ARP180100277A AR110963A1 AR 110963 A1 AR110963 A1 AR 110963A1 AR P180100277 A ARP180100277 A AR P180100277A AR P180100277 A ARP180100277 A AR P180100277A AR 110963 A1 AR110963 A1 AR 110963A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- coo
- unsubstituted
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Reivindicación 1: Un compuesto representado por la fórmula química (1), o una de sus sales farmacéuticamente aceptables, en la fórmula química (1), n es 1, ó 2; L es -CH₂CH₂-, -CH=C(R)-, o -CºC-, donde R es hidrógeno, C₁₋₄ alquilo, o halógeno; X¹ es CR¹R², NR¹, o -CO-; X² es CR³R⁴, o NR³, donde R¹ a R⁴ son cada uno de manera independiente hidrógeno, alquilo C₁₋₄, hidroxialquilo C₁₋₄, hidroxi, amino, carboxi, -COO(alquilo C₁₋₄), -CONH₂, -CONH(alquilo C₁₋₄), o -CON(alquilo C₁₋₄)₂; o pirazolilo no sustituido o sustituido con haloalquilo C₁₋₄; o R¹ y R³, juntos entre sí, unen X¹ y X² por medio de un doble enlace, y A es anillo benceno, piridina, pirimidina, o pirimidinadiona, en donde A está no sustituido o sustituido con uno a tres sustituyentes seleccionados cada uno independientemente del grupo que consiste de un sustituyente de tipo anillo seleccionado del grupo que consta de furanilo, imidazolilo, isoxazolilo, fenilo, pirazolilo, piridinonilo, piridinilo, pirrolilo, tiazolilo, y tiofenilo; alquilo C₁₋₄; alcoxi C₁₋₄; haloalquilo C₁₋₄; haloalcoxi C₁₋₄; halógeno; di(alquil C₁₋₄)amino; nitro; -COO(alquilo C₁₋₄); dihidropiranilo; morfolino; piperidinilo; y pirrolidinilo; y en donde el sustituyente de tipo anillo no está sustituido o está sustituido con uno o dos sustituyentes seleccionados cada uno independientemente del grupo que consiste en alquilo C₁₋₅, haloalquilo C₁₋₄, cicloalquilo C₃₋₆, monovalente de carbonato de alquileno C₂₋₅, -COO(alquilo C₁₋₄), halógeno, ciano, tiazolilo y (1,3-dioxolan-2-il)metilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170016971 | 2017-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110963A1 true AR110963A1 (es) | 2019-05-22 |
Family
ID=63107680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100277A AR110963A1 (es) | 2017-02-07 | 2018-02-06 | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10981917B2 (es) |
| EP (1) | EP3580208B1 (es) |
| JP (1) | JP6785384B2 (es) |
| KR (1) | KR102084772B1 (es) |
| CN (1) | CN110191882B (es) |
| AR (1) | AR110963A1 (es) |
| AU (1) | AU2018218965B2 (es) |
| BR (1) | BR112019016291A2 (es) |
| CA (1) | CA3049643C (es) |
| CL (1) | CL2019002019A1 (es) |
| CO (1) | CO2019007834A2 (es) |
| DO (1) | DOP2019000193A (es) |
| EC (1) | ECSP19051409A (es) |
| ES (1) | ES2899665T3 (es) |
| HR (1) | HRP20211483T1 (es) |
| HU (1) | HUE056218T2 (es) |
| MA (1) | MA47469B1 (es) |
| MX (1) | MX2019009185A (es) |
| MY (1) | MY196538A (es) |
| PE (1) | PE20191477A1 (es) |
| PH (1) | PH12019501811A1 (es) |
| PL (1) | PL3580208T3 (es) |
| PT (1) | PT3580208T (es) |
| RS (1) | RS62541B1 (es) |
| RU (1) | RU2733384C1 (es) |
| SA (1) | SA519402180B1 (es) |
| SG (1) | SG11201906436VA (es) |
| SI (1) | SI3580208T1 (es) |
| TN (1) | TN2019000204A1 (es) |
| TW (4) | TWI694070B (es) |
| WO (1) | WO2018147626A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213211A1 (en) * | 2017-05-15 | 2018-11-22 | The Regents Of The University Of Michigan | Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors |
| KR102346187B1 (ko) * | 2019-12-26 | 2021-12-31 | 울산과학기술원 | 디히드로퓨란 유도체 및 이의 합성 방법 |
| WO2022240035A1 (ko) | 2021-05-13 | 2022-11-17 | 주식회사 대웅제약 | 섬유화증의 예방 또는 치료용 약학적 조성물 |
| BR112023023670A2 (pt) | 2021-05-13 | 2024-01-30 | Daewoong Pharmaceutical Co Ltd | Composição farmacêutica para prevenir ou tratar fibrose |
| CN117693343A (zh) | 2021-07-23 | 2024-03-12 | 株式会社大熊制药 | 用于预防或治疗***性硬化症的药物组合物 |
| KR20230047910A (ko) * | 2021-10-01 | 2023-04-10 | 주식회사유한양행 | 바이사이클릭 융합환 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20230092630A (ko) * | 2021-12-17 | 2023-06-26 | 주식회사 대웅제약 | (2R, 3S)-2-(벤조[d]이미다졸일프로필)피페리딘-3-올 유도체의 제조 방법 |
| TW202334112A (zh) * | 2021-12-17 | 2023-09-01 | 南韓商大熊製藥股份有限公司 | (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形 |
| WO2023239166A1 (ko) * | 2022-06-08 | 2023-12-14 | 주식회사 대웅제약 | 아르기나아제 저해제 및 이를 포함하는 약학적 조성물 |
| WO2024080777A1 (ko) * | 2022-10-12 | 2024-04-18 | 주식회사 대웅제약 | 신장염의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8900719D0 (en) | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| DE59504622D1 (de) | 1994-10-31 | 1999-02-04 | Merck Patent Gmbh | Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren |
| IL114951A (en) | 1995-08-15 | 1999-08-17 | Hadasit Med Res Service | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization |
| WO1997034895A1 (de) * | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| CN1333028C (zh) * | 1999-08-20 | 2007-08-22 | Csl硅树脂公司 | 用作防腐蚀涂层的单组分有机聚硅氧烷橡胶组合物 |
| MXPA03008180A (es) | 2001-03-15 | 2003-12-12 | Astrazeneca Ab | Inhibidores de metaloproteinasa. |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| CN101247853B (zh) | 2005-04-13 | 2014-11-12 | 轴突公司 | 具有nos抑制活性的取代的吲哚化合物 |
| EP1939199A4 (en) * | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| WO2008101867A1 (en) | 2007-02-19 | 2008-08-28 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
| KR101649881B1 (ko) * | 2008-08-11 | 2016-08-30 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
| CA2737219C (en) | 2008-08-11 | 2017-02-28 | Tracy Keller | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| AU2013237881B2 (en) | 2012-03-29 | 2017-10-12 | Akashi Therapeutics, Inc. | Dosage forms of halofuginone and methods of use |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| WO2015199418A2 (ko) * | 2014-06-23 | 2015-12-30 | 주식회사 대웅제약 | 신규한 헤테로고리 화합물 |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
-
2018
- 2018-02-06 AR ARP180100277A patent/AR110963A1/es unknown
- 2018-02-07 CA CA3049643A patent/CA3049643C/en active Active
- 2018-02-07 CN CN201880006571.2A patent/CN110191882B/zh active Active
- 2018-02-07 MX MX2019009185A patent/MX2019009185A/es unknown
- 2018-02-07 TW TW107104338A patent/TWI694070B/zh active
- 2018-02-07 RS RS20211375A patent/RS62541B1/sr unknown
- 2018-02-07 MY MYPI2019004122A patent/MY196538A/en unknown
- 2018-02-07 TN TNP/2019/000204A patent/TN2019000204A1/en unknown
- 2018-02-07 TW TW109107089A patent/TWI772759B/zh active
- 2018-02-07 AU AU2018218965A patent/AU2018218965B2/en active Active
- 2018-02-07 MA MA47469A patent/MA47469B1/fr unknown
- 2018-02-07 SI SI201830416T patent/SI3580208T1/sl unknown
- 2018-02-07 PL PL18750794T patent/PL3580208T3/pl unknown
- 2018-02-07 JP JP2019542437A patent/JP6785384B2/ja active Active
- 2018-02-07 TW TW110116961A patent/TWI782525B/zh active
- 2018-02-07 HR HRP20211483TT patent/HRP20211483T1/hr unknown
- 2018-02-07 HU HUE18750794A patent/HUE056218T2/hu unknown
- 2018-02-07 SG SG11201906436VA patent/SG11201906436VA/en unknown
- 2018-02-07 PT PT187507942T patent/PT3580208T/pt unknown
- 2018-02-07 US US16/477,575 patent/US10981917B2/en active Active
- 2018-02-07 KR KR1020180015091A patent/KR102084772B1/ko active IP Right Grant
- 2018-02-07 WO PCT/KR2018/001625 patent/WO2018147626A1/en unknown
- 2018-02-07 TW TW108107266A patent/TWI700280B/zh active
- 2018-02-07 PE PE2019001462A patent/PE20191477A1/es unknown
- 2018-02-07 RU RU2019124878A patent/RU2733384C1/ru active
- 2018-02-07 BR BR112019016291A patent/BR112019016291A2/pt active Search and Examination
- 2018-02-07 ES ES18750794T patent/ES2899665T3/es active Active
- 2018-02-07 EP EP18750794.2A patent/EP3580208B1/en active Active
-
2019
- 2019-07-08 SA SA519402180A patent/SA519402180B1/ar unknown
- 2019-07-17 EC ECSENADI201951409A patent/ECSP19051409A/es unknown
- 2019-07-18 CL CL2019002019A patent/CL2019002019A1/es unknown
- 2019-07-22 CO CONC2019/0007834A patent/CO2019007834A2/es unknown
- 2019-07-24 DO DO2019000193A patent/DOP2019000193A/es unknown
- 2019-08-06 PH PH12019501811A patent/PH12019501811A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110963A1 (es) | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR114667A2 (es) | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina | |
| NZ732657A (en) | Picolinamides with fungicidal activity and other related compounds | |
| PH12015501929A1 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| PE20170677A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR098147A1 (es) | Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico | |
| NZ732812A (en) | Use of picolinamides and other compounds as fungicides | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR056582A1 (es) | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE | |
| DOP2010000226A (es) | Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos | |
| AR115662A2 (es) | Derivados de piperidina | |
| AR072726A1 (es) | Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c | |
| AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 | |
| AR096160A1 (es) | Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos | |
| AR081178A1 (es) | Derivados de heterociclos de nitrogeno, la preparacion y la aplicacion de los mismos en terapias de enfermedades mediadas por la inhibicion de scd-1. |